Sellas Life Sciences: REGAL Trial's Delayed Events Signal Selection Bias
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
Why Sellas Remains A Strong Sell After Doubling In Price
SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?
Sellas Life Sciences Shares Break Out To New 52-Week High: What's Driving The Momentum?
Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Event
SELLAS Stock Hits New Highs: What's Happening Today?
Why SELLAS Life Sciences Stock Is Surging Thursday
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers
Jim Cramer on SELLAS: “It’s a Great Spec”
SELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer Endorsement
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout
Sellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL Readout
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms
SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.